Mydecine Innovations Group Inc. (AQU:MYIG)
London flag London · Delayed Price · Currency is GBP · Price in GBX
1.750
0.00 (0.00%)
Inactive · Last trade price on Mar 31, 2025

Mydecine Innovations Group Company Description

Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions.

The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. Its lead product drug candidates include MYCO-005.

The company also develops MYCO-006 and MYCO-007. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds.

The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020.

Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Mydecine Innovations Group Inc.
CountryCanada
Founded2013
IndustryAgricultural Production Crops
CEODavid Bartch

Contact Details

Address:
1075 West Georgia Street
Vancouver, British Columbia V6E 3C9
Canada
Phone604 687 2038
Websitemydecine.com

Stock Details

Ticker SymbolMYIG
ExchangeAquis Exchange
Fiscal YearJanuary - December
Reporting CurrencyCAD
SIC Code0100

Key Executives

NamePosition
David BartchChief Executive Officer
John RossChief Financial Officer
Damon MichaelsChief Operating Officer